MINNEAPOLIS, Dec. 5 /PRNewswire/ -- Urologix, Inc. (Nasdaq: ULGX)
announced today that the underwriters in connection with the company's
secondary public offering have exercised their over-allotment option in full
to purchase an additional 225,000 shares of Urologix common stock.  The shares
were sold at the public offering price of $19.625 per share.  With the
exercise of the over-allotment option, Urologix has now issued a total of
1,725,000 shares in the offering and has 11,066,696 shares outstanding.
Urologix closed on the initial 1,500,000 shares on November 17, 1997.  The
shares were sold to the public through an underwriting syndicate headed by BT
Alex. Brown Incorporated, Dain Bosworth Incorporated and PaineWebber
Incorporated.
    The company intends to use the proceeds from the offering to fund sales
and marketing expenditures, to expand manufacturing capacity, and for working
capital and other general corporate purposes.
    Urologix, Inc., based in Minneapolis, develops, manufactures and markets
minimally invasive medical devices for the treatment of urological diseases.
The company has developed the Targis System(TM), a non-surgical,
anesthesia-free, catheter-based therapy that uses a proprietary microwave
technology for the treatment of benign prostatic hyperplasia (BPH), a disease
that affects over 23 million men worldwide.  The Targis System has been
approved for marketing in the United States, the European Union, Japan and
Canada.  The stock trades on the Nasdaq Stock Market under the symbol "ULGX."

Link to this page: